TerminatedNCT04847921
Addiction (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
Medication studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- AuroraSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 30, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 11
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT04847921
- Official title
Show the full official title
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections
Recruitment & locations
TerminatedAurora
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Does this study involve medication?
Yes. The study involves medication, including Dalbavancin.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
